[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 1965

Clinical Investigation of the Portacaval ShuntI. Study Design and Preliminary Survival Analysis

Author Affiliations

From the departments of medicine and surgery, Veterans Administration. Associate Professor of Surgery, University of Pittsburgh, School of Medicine (Dr. Jackson); Associate Professor, Department of Preventive Medicine, University of Washington, School of Medicine (Dr. Perrin); Assistant Clinical Professor of Medicine, University of California, Los Angeles (Dr. DeGradi); Assistant Professor of Pathology, Duke University School of Medicine (Dr. Smith); Director, Surgical Service, Veterans Administration, departments of medicine and surgery (Dr. Lee).

Arch Surg. 1965;91(1):43-54. doi:10.1001/archsurg.1965.01320130045006

THE ROLE of a portacaval shunt in the prevention of hemorrhage from esophagogastric varices and in the prolongation of life of patients with cirrhosis is unknown. Although two prospective studies1-4 have reported early survival analysis of this operation as a prophylaxis against hemorrhage and death from bleeding varices, there has been no controlled attempt to determine its effect upon the full spectrum of hepatic disease and the management of gastrointestinal hemorrhage.

Since Jan 1, 1962, investigators at 12 Veterans Administration hospitals have screened, classified, and randomized for therapy, patients admitted to their institutions and qualifying for the study under a uniform protocol. No patient was randomized until he was considered a satisfactory surgical risk and had agreed to accept an operation as a part of his treatment program. All patients were followed at regular intervals until death or lost to follow-up.

First Page Preview View Large
First page PDF preview
First page PDF preview